The multifaceted regulation and functions of PKM2 in tumor progression

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer - Tập 1846 - Trang 285-296 - 2014
Zongwei Li1, Peng Yang1, Zhuoyu Li1,2
1Institute of Biotechnology, Key Laboratory of Chemical Biology and Molecular Engineering of National Ministry of Education, Shanxi University, Taiyuan 030006, China
2College of Life Science, Zhejiang Chinese Medical University, Hangzhou 310053, China

Tài liệu tham khảo

Chaneton, 2012, Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer, Trends Biochem. Sci., 37, 309, 10.1016/j.tibs.2012.04.003

Mazurek, 2011, Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells, Int. J. Biochem. Cell Biol., 43, 969, 10.1016/j.biocel.2010.02.005

Christofk, 2008, The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth, Nature, 452, 230-U274, 10.1038/nature06734

Tamada, 2012, Pyruvate kinase m2: multiple faces for conferring benefits on cancer cells, Clin. Cancer Res., 18, 5554, 10.1158/1078-0432.CCR-12-0859

Schulze, 2000, The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer, Anticancer Res., 20, 4961

Wong, 2014, Changes in PKM2 associate with prostate cancer progression, Cancer Invest., 32, 330, 10.3109/07357907.2014.919306

Hardt, 2000, Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer, Anticancer Res., 20, 4965

Desai

Bluemlein, 2011, No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis, Oncotarget, 2, 393, 10.18632/oncotarget.278

Cortes-Cros, 2013, M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth, Proc. Natl. Acad. Sci. U. S. A., 110, 489, 10.1073/pnas.1212780110

Israelsen, 2013, PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells, Cell, 155, 397, 10.1016/j.cell.2013.09.025

Li, 2012, Diagnostic value of fecal tumor M2-pyruvate kinase for CRC screening: a systematic review and meta-analysis, Int. J. Cancer, 131, 1837, 10.1002/ijc.27442

Luo, 2011, Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1, Cell, 145, 732, 10.1016/j.cell.2011.03.054

Prigione, 2014, HIF1alpha modulates reprogramming through early glycolytic shift and up-regulation of PDK1-3 and PKM2, Stem Cells, 32, 364, 10.1002/stem.1552

Yang, 2012, EGFR-induced and PKCepsilon monoubiquitylation-dependent NF-kappaB activation upregulates PKM2 expression and promotes tumorigenesis, Mol. Cell, 48, 771, 10.1016/j.molcel.2012.09.028

Schafer, 1997, Glucose regulates the promoter activity of aldolase A and pyruvate kinase M2 via dephosphorylation of Sp1, FEBS Lett., 417, 325, 10.1016/S0014-5793(97)01314-8

Panasyuk, 2012, PPARgamma contributes to PKM2 and HK2 expression in fatty liver, Nat. Commun., 3, 672, 10.1038/ncomms1667

Nemazanyy, 2013, Role of PI3K, mTOR and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression, Biochem. Soc. Trans., 41, 917, 10.1042/BST20130034

Sun, 2011, Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth, Proc. Natl. Acad. Sci. U. S. A., 108, 4129, 10.1073/pnas.1014769108

Iqbal, 2013, Insulin enhances metabolic capacities of cancer cells by dual regulation of glycolytic enzyme pyruvate kinase M2, Mol. Cancer, 12, 10.1186/1476-4598-12-72

Wang, 2012, Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways, J. Hepatol., 57, 577, 10.1016/j.jhep.2012.04.026

David, 2010, HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer, Nature, 463, 364, 10.1038/nature08697

Clower, 2010, The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism, Proc. Natl. Acad. Sci. U. S. A., 107, 1894, 10.1073/pnas.0914845107

Chen, 2012, Concentration-dependent control of pyruvate kinase M mutually exclusive splicing by hnRNP proteins, Nat. Struct. Mol. Biol., 19, 346-U110, 10.1038/nsmb.2219

Wang, 2012, Exon-centric regulation of pyruvate kinase M alternative splicing via mutually exclusive exons, J. Mol. Cell Biol., 4, 79, 10.1093/jmcb/mjr030

Kefas, 2010, Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells, Neuro Oncol., 12, 1102, 10.1093/neuonc/noq080

Wong, 2008, Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling, Int. J. Cancer, 123, 251, 10.1002/ijc.23583

A.M. Liu, Z. Xu, F.H. Shek, K.F. Wong, N.P. Lee, R.T. Poon, J. Chen, J.M. Luk, miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma, PloS One, 9 (2014) e86872.

Rubinsztein, 2006, The roles of intracellular protein-degradation pathways in neurodegeneration, Nature, 443, 780, 10.1038/nature05291

Lv, 2011, Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth, Mol. Cell, 42, 719, 10.1016/j.molcel.2011.04.025

Huang, 2014, HSP40 interacts with pyruvate kinase M2 and regulates glycolysis and cell proliferation in tumor cells, PLoS One, 9, e92949, 10.1371/journal.pone.0092949

Yu, 2013, Proviral insertion in murine lymphomas 2 (PIM2) oncogene phosphorylates pyruvate kinase M2 (PKM2) and promotes glycolysis in cancer cells, J. Biol. Chem., 288, 35406, 10.1074/jbc.M113.508226

Hacker, 1998, Pyruvate kinase isoenzyme shift from l-type to M2-type is a late event in hepatocarcinogenesis induced in rats by a choline-deficient/DL-ethionine-supplemented diet, Carcinogenesis, 19, 99, 10.1093/carcin/19.1.99

Iqbal, 2014, Missense mutations in pyruvate kinase M2 promote cancer metabolism, oxidative endurance, anchorage independence and tumor growth in a dominant negative manner, J. Biol. Chem., 289, 8098, 10.1074/jbc.M113.515742

Greaves, 2012, Clonal evolution in cancer, Nature, 481, 306, 10.1038/nature10762

Visvader, 2011, Cells of origin in cancer, Nature, 469, 314, 10.1038/nature09781

Shih, 2001, Top-down morphogenesis of colorectal tumors, Proc. Natl. Acad. Sci. U. S. A., 98, 2640, 10.1073/pnas.051629398

Preston, 2003, Bottom-up histogenesis of colorectal adenomas: origin in the monocryptal adenoma and initial expansion by crypt fission, Cancer Res., 63, 3819

Torres-Montaner, 2011, Cancer origin in committed versus stem cells: hypothetical antineoplastic mechanism/s associated with stem cells, Crit. Rev. Oncol. Hematol., 80, 209, 10.1016/j.critrevonc.2011.01.003

Blanpain, 2013, Tracing the cellular origin of cancer, Nat. Cell Biol., 15, 126, 10.1038/ncb2657

Ricci-Vitiani, 2007, Identification and expansion of human colon-cancer-initiating cells, Nature, 445, 111, 10.1038/nature05384

Gao, 2012, Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase, Mol. Cell, 45, 598, 10.1016/j.molcel.2012.01.001

Ashizawa, 1991, In vivo regulation of monomer–tetramer conversion of pyruvate kinase subtype M2 by glucose is mediated via fructose 1,6-bisphosphate, J. Biol. Chem., 266, 16842, 10.1016/S0021-9258(18)55378-3

Luo, 2012, Emerging roles of PKM2 in cell metabolism and cancer progression, Trends Endocrinol. Metab., 23, 560, 10.1016/j.tem.2012.06.010

Ashizawa, 1991, An in vitro novel mechanism of regulating the activity of pyruvate kinase M2 by thyroid hormone and fructose 1, 6-bisphosphate, Biochemistry, 30, 7105, 10.1021/bi00243a010

Garreau, 1972, Allosteric activation of human erythrocyte pyruvate kinase by fructose-1,6-diphosphate. Kinetic and equilibrium binding studies, Biochimie, 54, 1103, 10.1016/S0300-9084(72)80013-0

Irving, 1973, Studies on the interaction between rabbit liver pyruvate kinase and its allosteric effector fructose 1,6-diphosphate, Biochem. J., 131, 303, 10.1042/bj1310303

Kahn, 1976, Pyruvate kinase isozymes in man. II. L type and erythrocyte-type isozymes. Electrofocusing and immunologic studies, Hum. Genet., 33, 35, 10.1007/BF00447284

Keller, 2012, SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions, Science, 338, 1069, 10.1126/science.1224409

Keller, 2014, SAICAR induces protein kinase activity of PKM2 that is necessary for sustained proliferative signaling of cancer cells, Mol. Cell, 53, 700, 10.1016/j.molcel.2014.02.015

Mellati, 1992, Regulation of M2-type pyruvate kinase from human meningioma by allosteric effectors fructose 1,6 diphosphate and l-alanine, Cancer Biochem. Biophys., 13, 33

T. Hitosugi, S. Kang, M.G. Vander Heiden, T.W. Chung, S. Elf, K. Lythgoe, S. Dong, S. Lonial, X. Wang, G.Z. Chen, J. Xie, T.L. Gu, R.D. Polakiewicz, J.L. Roesel, T.J. Boggon, F.R. Khuri, D.G. Gilliland, L.C. Cantley, J. Kaufman, J. Chen, Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth, Sci. Signal., 2 (2009) ra73.

Gao, 2013, Reciprocal regulation of protein kinase and pyruvate kinase activities of pyruvate kinase M2 by growth signals, J. Biol. Chem., 288, 15971, 10.1074/jbc.M112.448753

Bettaieb, 2013, Protein-tyrosine phosphatase 1B regulates pyruvate kinase M2 tyrosine phosphorylation, J. Biol. Chem., 288, 17360, 10.1074/jbc.M112.441469

Christofk, 2008, Pyruvate kinase M2 is a phosphotyrosine-binding protein, Nature, 452, 181-U127, 10.1038/nature06667

Varghese, 2010, Prolactin inhibits activity of pyruvate kinase M2 to stimulate cell proliferation, Mol. Endocrinol., 24, 2356, 10.1210/me.2010-0219

Lv, 2013, Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization, Mol. Cell, 52, 340, 10.1016/j.molcel.2013.09.004

D. Anastasiou, G. Poulogiannis, J.M. Asara, M.B. Boxer, J.-k. Jiang, M. Shen, G. Bellinger, A.T. Sasaki, J.W. Locasale, D.S. Auld, C.J. Thomas, M.G. Vander Heiden, L.C. Cantley, Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses, Science, 334 (2011) 1278–1283.

Moellering, 2013, Functional lysine modification by an intrinsically reactive primary glycolytic metabolite, Science, 341, 549, 10.1126/science.1238327

Zhou, 2013, Mass spectrometric analysis reveals O-methylation of pyruvate kinase from pancreatic cancer cells, Anal. Bioanal. Chem., 405, 4937, 10.1007/s00216-013-6880-7

Spoden, 2009, The SUMO-E3 ligase PIAS3 targets pyruvate kinase M2, J. Cell. Biochem., 107, 293, 10.1002/jcb.22125

Kosugi, 2011, MUC1-C oncoprotein regulates glycolysis and pyruvate kinase M2 activity in cancer cells, PLoS One, 6, e28234, 10.1371/journal.pone.0028234

Mor, 2012, Death-associated protein kinase increases glycolytic rate through binding and activation of pyruvate kinase, Oncogene, 31, 683, 10.1038/onc.2011.264

Wang, 2014, JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1alpha-mediated glucose metabolism, Proc. Natl. Acad. Sci. U. S. A., 111, 279, 10.1073/pnas.1311249111

Shimada, 2008, Modulation of M2-type pyruvate kinase activity by the cytoplasmic PML tumor suppressor protein, Genes Cells, 13, 245, 10.1111/j.1365-2443.2008.01165.x

Zwerschke, 1999, Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein, Proc. Natl. Acad. Sci. U. S. A., 96, 1291, 10.1073/pnas.96.4.1291

Hoshino, 2007, Regulation of cell proliferation by interleukin-3-induced nuclear translocation of pyruvate kinase, J. Biol. Chem., 282, 17706, 10.1074/jbc.M700094200

McDonnell, 2013, Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK-mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma, Blood, 122, 958, 10.1182/blood-2013-01-482026

Wong, 2014, PKM2 contributes to cancer metabolism, Cancer Lett.

Gui, 2013, Allosteric regulation of PKM2 allows cellular adaptation to different physiological states, Sci. Signal., 6, e7, 10.1126/scisignal.2003925

Morgan, 2013, M2 pyruvate kinase provides a mechanism for nutrient sensing and regulation of cell proliferation, Proc. Natl. Acad. Sci. U. S. A., 110, 5881, 10.1073/pnas.1217157110

Bluemlein, 2012, Pyruvate kinase is a dosage-dependent regulator of cellular amino acid homeostasis, Oncotarget, 3, 1356, 10.18632/oncotarget.730

Chaneton, 2012, Serine is a natural ligand and allosteric activator of pyruvate kinase M2, Nature, 491, 458, 10.1038/nature11540

Ye, 2012, Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation, Proc. Natl. Acad. Sci. U. S. A., 109, 6904, 10.1073/pnas.1204176109

Kung, 2012, Small molecule activation of PKM2 in cancer cells induces serine auxotrophy, Chem. Biol., 19, 1187, 10.1016/j.chembiol.2012.07.021

Yang, 2012, ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect, Nat. Cell Biol., 14, 1295, 10.1038/ncb2629

Yang, 2011, Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation, Nature, 480, 118, 10.1038/nature10598

Yang, 2012, PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis, Cell, 150, 685, 10.1016/j.cell.2012.07.018

Yang, 2013, Nuclear PKM2 regulates the Warburg effect, Cell Cycle, 12, 3154, 10.4161/cc.26182

Jiang, 2014, PKM2 regulates chromosome segregation and mitosis progression of tumor cells, Mol. Cell, 53, 75, 10.1016/j.molcel.2013.11.001

DeBerardinis, 2008, The biology of cancer: metabolic reprogramming fuels cell growth and proliferation, Cell Metab., 7, 11, 10.1016/j.cmet.2007.10.002

Salama, 2014, Estradiol-17beta upregulates Pyruvate kinase M2 expression to co-activate estrogen receptor-alpha and to integrate metabolic reprogramming with the mitogenic response in endometrial cells, J. Clin. Endocrinol. Metab., jc20132639

Lee, 2008, Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription, Int. J. Biochem. Cell Biol., 40, 1043, 10.1016/j.biocel.2007.11.009

Kwon, 2012, Pyruvate kinase M2 promotes the growth of gastric cancer cells via regulation of Bcl-xL expression at transcriptional level, Biochem. Biophys. Res. Commun., 423, 38, 10.1016/j.bbrc.2012.05.063

Goldberg, 2012, Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression, J. Exp. Med., 209, 217, 10.1084/jem.20111487

Spoden, 2009, Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply, Exp. Cell Res., 315, 2765, 10.1016/j.yexcr.2009.06.024

Stetak, 2007, Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death, Cancer Res., 67, 1602, 10.1158/0008-5472.CAN-06-2870

Zhou, 2012, Pyruvate kinase type M2 is upregulated in colorectal cancer and promotes proliferation and migration of colon cancer cells, Iubmb Life, 64, 775, 10.1002/iub.1066

Wang, 2013, Pyruvate kinase M2 plays a dual role on regulation of the EGF/EGFR signaling via E-cadherin-dependent manner in gastric cancer cells, PLoS One, 8, e67542, 10.1371/journal.pone.0067542

Dhar, 2013, Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer, Cancer, 119, 575, 10.1002/cncr.27611

Yang, 2014, Pyruvate kinase M2 facilitates colon cancer cell migration via the modulation of STAT3 signalling, Cell. Signal., 26, 1853, 10.1016/j.cellsig.2014.03.020

Yin, 2013, The value of expression of M2-PK and VEGF in patients with advanced gastric cancer, Cell Biochem. Biophys., 67, 1033, 10.1007/s12013-013-9601-0

Wittwer, 2011, Enhancing mitochondrial respiration suppresses tumor promoter TPA-induced PKM2 expression and cell transformation in skin epidermal JB6 cells, Cancer Prev. Res. (Phila.), 4, 1476, 10.1158/1940-6207.CAPR-11-0028

Meganathan, 2012, Identification of thalidomide-specific transcriptomics and proteomics signatures during differentiation of human embryonic stem cells, PLoS One, 7, e44228, 10.1371/journal.pone.0044228

Morfouace, 2014, Control of glioma cell death and differentiation by PKM2–Oct4 interaction, Cell Death Dis., 5, e1036, 10.1038/cddis.2013.561

Tamada, 2012, Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells, Cancer Res., 72, 1438, 10.1158/0008-5472.CAN-11-3024

Vermeulen, 2010, Wnt activity defines colon cancer stem cells and is regulated by the microenvironment, Nat. Cell Biol., 12, 468, 10.1038/ncb2048

McAllister, 2010, Tumor–host interactions: a far-reaching relationship, J. Clin. Oncol., 28, 4022, 10.1200/JCO.2010.28.4257

Kaplan, 2007, Niche-to-niche migration of bone-marrow-derived cells, Trends Mol. Med., 13, 72, 10.1016/j.molmed.2006.12.003

Karnoub, 2007, Mesenchymal stem cells within tumour stroma promote breast cancer metastasis, Nature, 449, 557, 10.1038/nature06188

Mantovani, 2008, Cancer-related inflammation, Nature, 454, 436, 10.1038/nature07205

Pavlides, 2010, The autophagic tumor stroma model of cancer: role of oxidative stress and ketone production in fueling tumor cell metabolism, Cell Cycle, 9, 3485, 10.4161/cc.9.17.12721

Chiavarina, 2011, Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth, Cancer Biol. Ther., 12, 1101, 10.4161/cbt.12.12.18703

Bonuccelli, 2010, The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts, Cell Cycle, 9, 1960, 10.4161/cc.9.10.11601

Nouri-Shirazi, 2000, Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses, J. Immunol., 165, 3797, 10.4049/jimmunol.165.7.3797

Bennaceur, 2008, Dendritic cells dysfunction in tumour environment, Cancer Lett., 272, 186, 10.1016/j.canlet.2008.05.017

Liao, 2007, Modification of the tumor microenvironment to enhance immunity, Front. Biosci., 12, 3576, 10.2741/2336

Zhang, 2010, Antigen presentation by dendritic cells in tumors is disrupted by altered metabolism that involves pyruvate kinase M2 and its interaction with SOCS3, Cancer Res., 70, 89, 10.1158/0008-5472.CAN-09-2970

Vander Heiden, 2010, Evidence for an alternative glycolytic pathway in rapidly proliferating cells, Science, 329, 1492, 10.1126/science.1188015

Chung-Faye, 2007, Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation, Inflamm. Bowel Dis., 13, 1374, 10.1002/ibd.20214

Koss, 2008, Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention, Colorectal Dis., 10, 244, 10.1111/j.1463-1318.2007.01334.x

Hardt, 2004, Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer, Br. J. Cancer, 91, 980, 10.1038/sj.bjc.6602033

Hardt, 2008, Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy, Expert. Rev. Mol. Diagn., 8, 579, 10.1586/14737159.8.5.579

Tonus, 2012, Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis, World J. Gastroenterol., 18, 4004, 10.3748/wjg.v18.i30.4004

Ewald, 2007, Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer, Anticancer Res., 27, 1949

Meng, 2012, Serum M2-pyruvate kinase: a promising non-invasive biomarker for colorectal cancer mass screening, World J. Gastrointest. Oncol., 4, 145, 10.4251/wjgo.v4.i6.145

Hathurusinghe, 2007, Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy, Ann. Surg. Oncol., 14, 2714, 10.1245/s10434-007-9481-x

Kumar, 2007, Tumour M2-pyruvate kinase: a gastrointestinal cancer marker, Eur. J. Gastroenterol. Hepatol., 19, 265, 10.1097/MEG.0b013e3280102f78

Zhang, 2004, Tumor type M-2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls, World J. Gastroenterol., 10, 1643, 10.3748/wjg.v10.i11.1643

Ugurel, 2005, Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma, Int. J. Cancer, 117, 825, 10.1002/ijc.21073

Landt, 2010, Tumor-specific correlation of tumor M2 pyruvate kinase in pre-invasive. Invasive and Recurrent Cervical Cancer, Anticancer Res., 30, 375

Novotny, 2008, Tumor marker M2-pyruvate-kinase in differential diagnosis of chronic pancreatitis and pancreatic cancer, Hepatogastroenterology, 55, 1475

Wechsel, 1999, Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK), Anticancer Res., 19, 2583

B. Nisman, V. Yutkin, H. Nechushtan, O.N. Gofrit, T. Peretz, S. Gronowitz, D. Pode, Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy, Urology, 76 (2010) 513.e511-516.

Fatela-Cantillo, 2012, Prognostic value of plasmatic tumor M2 pyruvate kinase and carcinoembryonic antigen in the survival of colorectal cancer patients, Tumour Biol., 33, 825, 10.1007/s13277-011-0304-0

Shastri, 2006, Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia, Int. J. Cancer, 119, 2651, 10.1002/ijc.22243

Shastri, 2008, Faecal tumour pyruvate kinase M2: not a good marker for the detection of colorectal adenomas, Br. J. Cancer, 99, 1367-1366, 10.1038/sj.bjc.6604656

author reply 1367.

Shastri, 2008, Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: Prospective multicenter study, Am. J. Gastroenterol., 103, 1496, 10.1111/j.1572-0241.2008.01824.x

Haug, 2008, Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study, Br. J. Cancer, 99, 133, 10.1038/sj.bjc.6604427

Li, 2012, Diagnostic value of fecal tumor M2-pyruvate kinase for CRC screening: a systematic review and meta-analysis, Int. J. Cancer, 131, 1837, 10.1002/ijc.27442

Ervens, 2008, Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer, J. Craniomaxillofac. Surg., 36, 89, 10.1016/j.jcms.2007.08.006

Varga, 2002, Determination of pyruvate kinase type tumor M2 in human renal cell carcinoma: a suitable tumor marker?, Urol. Res., 30, 122, 10.1007/s00240-002-0246-5

Koss, 2004, The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia–dysplasia–adenocarcinoma sequence in Barrett's oesophagus, J. Clin. Pathol., 57, 1156, 10.1136/jcp.2004.018150

Staib, 2006, Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors, Clin. Chem. Lab. Med., 44, 28, 10.1515/CCLM.2006.006

Vander Heiden, 2010, Identification of small molecule inhibitors of pyruvate kinase M2, Biochem. Pharmacol., 79, 1118, 10.1016/j.bcp.2009.12.003

Guo, 2011, Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model, J. Cancer Res. Clin. Oncol., 137, 65, 10.1007/s00432-010-0860-5

Jiang, 2012, Cyclosporine A inhibits breast cancer cell growth by downregulating the expression of pyruvate kinase subtype M2, Int. J. Mol. Med., 30, 302, 10.3892/ijmm.2012.989

Iqbal, 2012, Resveratrol Inhibits Cancer Cell Metabolism by Down Regulating Pyruvate Kinase M2 via Inhibition of Mammalian Target of Rapamycin, Plos One, 7, 10.1371/journal.pone.0036764

Chen, 2011, Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2, Oncogene, 30, 4297, 10.1038/onc.2011.137

Chen, 2012, Vitamin K-3 and K-5 are inhibitors of tumor pyruvate kinase M2, Cancer Lett., 316, 204, 10.1016/j.canlet.2011.10.039

Liu, 2014, Oleanolic acid suppresses aerobic glycolysis in cancer cells by switching pyruvate kinase type m isoforms, PLoS One, 9, e91606, 10.1371/journal.pone.0091606

Spoden, 2008, Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation, Int. J. Cancer, 123, 312, 10.1002/ijc.23512

Jiang, 2010, Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase, Bioorg. Med. Chem. Lett., 20, 3387, 10.1016/j.bmcl.2010.04.015

Yacovan, 2012, 1-(sulfonyl)-5-(arylsulfonyl)indoline as activators of the tumor cell specific M2 isoform of pyruvate kinase, Bioorg. Med. Chem. Lett., 22, 6460, 10.1016/j.bmcl.2012.08.054

Walsh, 2011, 2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase, Bioorg. Med. Chem. Lett., 21, 6322, 10.1016/j.bmcl.2011.08.114

Xu, 2014, Discovery of 3-(trifluoromethyl)-1H-pyrazole-5-carboxamide activators of the M2 isoform of pyruvate kinase (PKM2), Bioorg. Med. Chem. Lett., 24, 515, 10.1016/j.bmcl.2013.12.028

Boxer, 2010, Evaluation of substituted N,N′-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase, J. Med. Chem., 53, 1048, 10.1021/jm901577g

M.J. Walsh, K.R. Brimacombe, D. Anastasiou, Y. Yu, W.J. Israelsen, B.S. Hong, W. Tempel, S. Dimov, H. Veith, H. Yang, C. Kung, K.E. Yen, L. Dang, F. Salituro, D.S. Auld, H.W. Park, M.G. Vander Heiden, C.J. Thomas, M. Shen, M.B. Boxer, ML265: A potent PKM2 activator induces tetramerization and reduces tumor formation and size in a mouse xenograft model, 2012 Mar 16 [Updated 2013 May 8]. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK153222/. PMID: 23905203.

Anastasiou, 2012, Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis, Nat. Chem. Biol., 8, 839, 10.1038/nchembio.1060

Spoden, 2008, Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation, Int. J. Cancer, 123, 312, 10.1002/ijc.23512

Hamanaka, 2012, Targeting glucose metabolism for cancer therapy, J. Exp. Med., 209, 211, 10.1084/jem.20120162

Parnell, 2013, Pharmacologic activation of PKM2 slows lung tumor xenograft growth, Mol. Cancer Ther., 12, 1453, 10.1158/1535-7163.MCT-13-0026

Cairns, 2011, Regulation of cancer cell metabolism, Nat. Rev. Cancer, 11, 85, 10.1038/nrc2981

Jain, 2012, Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation, Science, 336, 1040, 10.1126/science.1218595

Dombrauckas, 2005, Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis, Biochemistry, 44, 9417, 10.1021/bi0474923

Thông tin
Thông tin xuất bản

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

Tập 1846

285-296

Thông tin tác giả